1. Introduction
===============

Recently, the compounds with cyclic structures derived from the \[2.2\] paracyclophane backbone **1** ([Figure 1](#molecules-14-01546-f001){ref-type="fig"}) have stimulated considerable interest due to their special properties and applications. 4,12-Bis(diphenylphosphino)-\[2.2\]-paracyclophane was shown to be an excellent transition metal ligand for the catalytic asymmetric hydrogenation of carbonyl groups \[[@B1-molecules-14-01546],[@B2-molecules-14-01546],[@B3-molecules-14-01546],[@B4-molecules-14-01546]\]. The bridge-fluorinated paracyclophanes display intriguing chemical reactivity \[[@B5-molecules-14-01546],[@B6-molecules-14-01546],[@B7-molecules-14-01546]\] and commercial applications \[[@B8-molecules-14-01546],[@B9-molecules-14-01546]\]. The bridging ligands derived from paracyclophane have afforded the opportunity to investigate the role of π--stacking interactions in mediating electronic communication, as charge-transport was observed in double-stranded DNA \[[@B10-molecules-14-01546],[@B11-molecules-14-01546],[@B12-molecules-14-01546]\]. It is believed that the cyclic face-to-face rigid structure of the paracyclophane moiety plays an important role in properties of these derivatives.

![The structure of \[2.2\] paracyclophane.](molecules-14-01546-g001){#molecules-14-01546-f001}

In a recent communication \[[@B13-molecules-14-01546]\], we reported the synthesis of zwitterionic 4-hydroxycoumarin derivatives. We now describe the novel pseudo-cyclic face-to-face rigid structures of these zwitterions ([Figure 2](#molecules-14-01546-f002){ref-type="fig"}).

![The zwitterion structures.](molecules-14-01546-g002){#molecules-14-01546-f002}

2. Results and Discussion
=========================

The zwitterionic 4-hydroxycoumarin derivatives are composed of hydroquinone, pyridine and 4-hydroxycoumarin planes. The pyridine and 4-hydroxycoumarin planes are joined to the hydroquinone core to form the pseudo-cyclic face-to-face structure ([Figure 2](#molecules-14-01546-f002){ref-type="fig"}).

The different ^1^H-NMR shifts of the two α-protons located on the pyridine ring of **2b** \[[@B13-molecules-14-01546]\] indicated that the pyridine plane cannot rotate freely at room temperature, as it is known that if the pyridine ring can rotate freely, the two α-protons do not give separate ^1^H-NMR signals. Moreover, when *N*-heterocyclic aromatics such as 3-methylpyridine and quinoline (which lack a C~2~-symmetric axis through the nitrogen atom) were treated with 4-hydroxycoumarins and *p*-benzoquinone, both *cis* and *trans* products were obtained, due to the restricted rotation about the C-N bond. The results of these reactions are summarized in [Table 1](#molecules-14-01546-t001){ref-type="table"} and [Table 2](#molecules-14-01546-t002){ref-type="table"}.

These *cis* and *trans* products could not be separated by silica gel column chromatography. The assignment of the respective stereochemistry and their isomer ratios could however be established from the ^1^H-NMR spectra. For the 3-methylpyridinium zwitterion **3a**, the α-proton next to the methyl group on the pyridine ring was predicted to only show a single peak in the aromatic region ([Figure 3](#molecules-14-01546-f003){ref-type="fig"}). The appearance of the two aromatic singlets, at *δ* 8.92 and 8.51 ppm, respectively, implied that both *cis* and *trans* isomers might be generated. Futhermore, the two aromatic singlets had a total integrated area equal to 1H, consistent with a mixture of the two isomers. The peak at *δ* 8.92 was attributed to the α-proton (H2) adjacent to the methyl group of *cis* isomer, in which H2 was is further away from the shielding region of the oxyanion, and came at low fields relative to H2' of the *trans* isomer. Thus the area ratio of 1.3:1 of the two aromatic singlets represents the *cis* and *trans* isomer ratio.

molecules-14-01546-t001_Table 1

###### 

The synthesis of 3-methylpyridinium zwitterions.
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The synthesis of quinolinium zwitterions.
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![The ^1^H-NMR spectra of compounds **2a** and **3a**.](molecules-14-01546-g003){#molecules-14-01546-f003}

The chemical shifts and the integration of the peaks of the ^1^H-NMR spectrum did not change even when the sample of **2b** and **4a** was warmed. ([Figure 4](#molecules-14-01546-f004){ref-type="fig"} and [Figure 5](#molecules-14-01546-f005){ref-type="fig"}) This showed that the zwitterionic 4-hydroxycoumarin derivatives were very stable. However, pyridium zwitterions are generally considered to be reactive species and unstable \[[@B14-molecules-14-01546]\]. The characteristic features of the ^1^H-NMR spectra of the zwitterions at different temperatures indicated that the zwitterionic 4-hydroxycoumarin derivatives possessed a rigid backbone containing two defined face-to-face planes, just likes \[2.2\] paracyclophanes do. However, \[2.2\] paracyclophane is a macrocyclic ring, and the zwitterions just were pseudo-cyclic.

![The ^1^H-NMR spectra of compound **2b** at 30 °C and 70 °C.](molecules-14-01546-g004){#molecules-14-01546-f004}

![The ^1^H-NMR spectra of compound **4a** at 30 °C and 80 °C.](molecules-14-01546-g005){#molecules-14-01546-f005}

Emadi *et al*. \[[@B15-molecules-14-01546]\] have reported a trimeric compound **5** ([Figure 6](#molecules-14-01546-f006){ref-type="fig"}), with structural features similar to those of zwitterionic 4-hydroxycoumarin derivatives. In compound **5** the presence of conjugation between the naphthoquinone and the two (2-hydroxynaphthoquinone) subunits was suggested. This conjugation implied that the subunit could rotate along the bond joining the subunit to the quinone core and a rigid structure wasn't generated.

![The structure of compound **5**.](molecules-14-01546-g006){#molecules-14-01546-f006}

The face-to-face rigid backbone of the zwitterions was assumed to be caused by both the intramolecular ion pair attraction and the steric interaction ([Figure 7](#molecules-14-01546-f007){ref-type="fig"}). The ion pair attraction made the 4-hydroxycoumarin ring tilt toward the pyridine ring until the equilibration between the ion pair attraction and the steric interaction was reached and the rings could remain stable at a certain angle. Conversely, the tilted 4-hydroxycoumarin ring constrained the pyridine from rotating freely through steric interactions.

![The intramolecular ion pair attraction and steric interaction of the zwitterion.](molecules-14-01546-g007){#molecules-14-01546-f007}

3. Experimental
===============

3.1. General
------------

^1^H-NMR spectra were measured at room temperature (except for the temperature dependence studies) on a Varian UNITY INOVA 500 MHz spectrometer using TMS as an internal standard. For the electrospray (ESI) MS analysis, a Finnigan LCQ Deca XP ion trap mass spectrometer equipped with a Microsoft Windows NT data system and an ESI interface was used. Elementary analysis was recorded on an Elementar Vario EL elementary analysis device. IR spectra were recorded on a Bruker TENSOR 37 spectrophotometer.

3.2. General procedure: synthesis of 4-hydroxycoumarin zwitterions
------------------------------------------------------------------

A mixture of 4-hydroxycoumarin (5 mmol), *p*-benzoquinone (1.08 g, 10 mmol) and the appropriate *N*-heterocyclic aromatic (10 mmol) was magnetically stirred in aqueous acetone (30 mL, v:v = 1:1) at room temperature for 24 h. The reaction mixture was filtered to afford a brown crude product which was purified by column chromatography (silica gel, methanol-chloroform = 1:10) to give yellow compounds.

*Cis and trans 3-(3,6-Dihydroxy-2-(3-methylpyridinium-1-yl)phenyl)-2-oxo-2H-chromen-4-olate* (**3a** and **3a'**): yield 39%; **3a**:**3a'** = 1.3:1; ^1^H-NMR (DMSO-*d~6~*) δ 2.25 (3H, s) ppm; IR: 3404, 3060, 1649, 1597, 1505, 1445 cm^-1^; ESI-MS (*m/e*): 360 (M-1)^-^; Anal. Calcd. for C~21~H~15~NO~5~: C, 69.80%; H, 4.18%; N, 3.88%. Found: C, 69.47%; H, 4.35%; N, 4.02%.

*Cis and trans 3-(3,6-dihydroxy-2-(3-methylpyridinium-1-yl)phenyl)-8-methyl-2-oxo-2H-chromen-4-olate* (**3b** and **3b'**): yield 35%, **3b**:**3b'** = 1.3:1; ^1^H-NMR (DMSO-*d~6~*) δ 2.25 (3H, s), 2.21 (3H, s) ppm; IR: 3062, 1620, 1504, 1424, 1335, 1278 cm^-1^; ESI-MS (*m/e*): 374 (M-1)^-^; Anal. Calcd. for C~22~H~17~NO~5~: C, 70.39%; H, 4.56%; N, 3.73%. Found: C, 69.56%; H, 4.73%; N, 3.95%.

*Cis and trans 3-(3,6-dihydroxy-2-(3-methylpyridinium-1-yl)phenyl)-7-methyl-2-oxo-2H-chromen-4-olate* (**3c** and **3c'**): yield 29%; **3c**:**3c'** = 1.2:1; ^1^H-NMR (DMSO-*d~6~*) δ 2.67 (3H, s), 2.29 (3H, s) ppm; IR: 2924, 1603, 1501, 1434, 1272 cm^-1^; ESI-MS (*m/e*): 374 (M-1)^-^; Anal. Calcd. for C~22~H~17~NO~5~: C, 70.39%; H, 4.56%; N, 3.73%. Found: C, 70.15%; H, 4.81%; N, 3.87%.

*Cis and trans 3-(3,6-dihydroxy-2-(3-methylpyridinium-1-yl)phenyl)-6-methyl-2-oxo-2H-chromen-4-olate* (**3d** and **3d'**): yield 42%; **3d**:**3d'** = 1.3:1; ^1^H-NMR (DMSO-*d~6~*) δ 2.32 (3H, s), 2.24 (3H, s) ppm; IR: 3394, 1641, 1504, 1512, 1270 cm^-1^; ESI-MS (*m/e*): 374 (M-1)^-^; Anal. Calcd. for C~22~H~17~NO~5~: C, 70.39%; H, 4.56%; N, 3.73%. Found: C, 70.22%; H, 4.63%; N, 3.81%.

*Cis and trans 3-(3,6-dihydroxy-2-(3-methylpyridinium-1-yl)phenyl)-2-oxo-2H-benzo\[h\]chromen-4-olate* (**3e** and **3e'**): yield 37%; **3e**:**3e'**= 1.1:1; ^1^H-NMR (DMSO-*d~6~*) δ 2.22 (3H, s) ppm; IR: 3068, 1638, 1478, 1271 cm^-1^; ESI-MS (*m/e*): 410 (M-1)^-^; Anal. Calcd. for C~25~H~17~NO~5~: C, 72.99%; H, 4.16%; N, 3.40%. Found: C, 72.67%; H, 4.57%; N, 3.76%.

*Cis and trans 2-(3,6-dihydroxy-2-(3-methylpyridinium-1-yl)phenyl)-3-oxo-3H-benzo\[f\]chromen-1-olate* (**3f** and **3f'**): yield 31%; **3f**:**3f'** = 1.1:1; ^1^H-NMR (DMSO-*d~6~*) δ 2.24 (3H, s) ppm; IR: 3059, 1632, 1507, 1266 cm^-1^; ESI-MS (*m/e*): 410 (M-1)^-^; Anal. Calcd for C~25~H~17~NO~5:~ C, 72.99%; H, 4.16%; N, 3.40%. Found: C, 72.63%; H, 4.51%; N, 3.69%.

*Cis and trans 3-(3,6-dihydroxy-2-(quinolinium-1-yl)phenyl)-2-oxo-2H-chromen-4-olate* (**4a** and **4a'**): yield 15%, **4a**(*cis*):**4a'**(*trans*) = 1:1.6; IR: 3093, 1639, 1513, 1274 cm^-1^; ESI-MS (*m/e*): 396 (M-1)^-^; Anal. Calcd for C~24~H~15~NO~5~: C, 72.54%; H, 3.80%; N, 3.52%. Found: C, 72.55%; H, 3.91%; N, 3.65%.

*Cis and trans 3-(3,6-dihydroxy-2-(quinolinium-1-yl)phenyl)-8-methyl-2-oxo-2H-chromen-4-olate* (**4b** and **4b'**): yield 12%; **4b**(*cis*):**4b'**(*trans*) = 1:1.3; ^1^H-NMR (DMSO-*d~6~*) δ 9.39 (0.56H, s), 8.83 (0.44H, br), 2.10 (3H, s) ppm; IR: 3391, 1635, 1516, 1274 cm^-1^; ESI-MS (*m/e*): 410 (M-1)^-^, Anal. Calcd for C~25~H~17~NO~5~: C, 72.99%; H, 4.16%; N, 3.40%. Found: C, 72.74%; H, 4.32%; N, 3.55%.

*Cis and trans 3-(3,6-dihydroxy-2-(quinolinium-1-yl)phenyl)-7-methyl-2-oxo-2H-chromen-4-olate* (**4c** and **4c'**): yield 9%; **4c**(*cis*):**4c'**(*trans*) = 1:1.4; ^1^H-NMR (DMSO-*d~6~*) δ 2.24 (3H, s) ppm, IR: 3432, 1605, 1508 cm^-1^; ESI-MS *(m/e*): 410 (M-1)^-^; Anal. Calcd. for C~25~H~17~NO~5~: C, 72.99%; H, 4.16%; N, 3.40%. Found: C, 72.77%; H, 4.33%; N, 3.46%.

*Cis and trans 3-(3,6-dihydroxy-2-(quinolinium-1-yl)phenyl)-6-methyl-2-oxo-2H-chromen-4-olate* (**4d** and **4d'**): yield 16%, **4d**:**4d'**= 1:1.7, ^1^H-NMR (DMSO-*d~6~*) δ 2.25 (3H, s) ppm; IR: 3366, 1641, 1512, 1277 cm^-1^; ESI-MS (*m/e*): 410 (M-1)^-^; Anal. Calcd. for C~25~H~17~NO~5~: C, 72.99%; H, 4.16%; N, 3.40%. Found: C, 72.83%; H, 4.26%; N, 3.43%.

*Cis and trans 3-(3,6-dihydroxy-2-(quinolinium-1-yl)phenyl)-2-oxo-2H-benzo\[h\]chromen-4-olate* (**4e** and **4e'**): yield 13%; **4e**:**4e'**= 1.3:1; IR: 3090, 1638, 1578, 1524, 1272 cm^-1^; ESI-MS (*m/e*): 410 (M-1)^-^; Anal. Calcd. for C~28~H~17~NO~5~: C, 75.16%; H, 3.83%; N, 3.13%. Found: C, 75.06%; H, 3.93%; N, 3.28%.

*Cis and trans 2-(3,6-dihydroxy-2-(quinolinium-1-yl)phenyl)-3-oxo-3H-benzo\[f\]chromen-1-olate* (**4f** and **4f'**): yield 12%, **4f**:**4f'** = 1:1.5; IR: 3094, 1629, 1512, 1270 cm^-1^; ESI-MS (*m/e*): 410 (M-1)^-^; Anal. Calcd for C~28~H~17~NO~5~: C, 75.16%; H, 3.83%; N, 3.13%. Found: C, 75.31%; H, 3.98%; N, 3.24%.
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